Young Epilepsy relaunches sodium valproate survey with Epilepsy Society and Epilepsy Action
Young Epilepsy, Epilepsy Action and Epilepsy Society have launched a survey for women, aged 16-50, to find out how aware they are of the potential risks of taking sodium valproate, during pregnancy.
This is an updated survey to the one orchestrated in 2016.
Sodium valproate is available under various names including Epilim, Episenta, Epival, Convulex and Depakote. Valproate use, during pregnancy, can potentially harm the physical health and development of a child. Up to four in ten babies are at risk of developmental disorders, with approximately one in ten at risk of birth defects.
The interim results of this survey will be released on Tuesday, 26 September 2016 during the European Medicines Agency (EMA)’s public hearing in London. This hearing is about sodium valproate and its potential risks to pregnant women. Outcomes from this survey will help the EMA with their findings.
The full results are expected to be released in November 2017.
The results from this survey will give an indication on whether health professionals are improving their practice, in comparison to 2016. This would therefore help us in creating solutions for pregnant women, who aren’t informed about the potential risks sodium valproate poses. Women and girls of child-bearing potential should only be treated with sodium valproate if nothing else works. It is crucial women and girls do not stop taking their epilepsy medication without talking to a healthcare professional beforehand.
Last year’s findings are found here.